Royalty Pharma plc 4

EVP & CFO Terrance P. Coyne, through TPC RP EPA1 LLC, sold a total of 11,002 Royalty Pharma plc Class A Ordinary Shares on August 13, 2026 for roughly $645,000 under a 10b5-1 plan.

On August 13, 2026, Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, effected two open-market sales of Royalty Pharma Class A Ordinary Shares pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 24, 2026. Through an entity, TPC RP EPA1 LLC, he sold 9,230 shares at a weighted average price of approximately $58.59 per share, for about $540,000, and an additional 1,772 shares at a weighted average price of approximately $59.14 per share, for about $105,000, with both trades executed in multiple transactions within disclosed price ranges. After these sales, indirect holdings via TPC RP EPA1 LLC were reduced to zero, while Mr. Coyne continues to own additional Class A Ordinary Shares indirectly through family and IRA accounts and also holds substantial exchangeable interests and Class E Ordinary Shares in affiliated entities that are convertible into millions of additional Class A shares, some of which remain subject to vesting conditions.

Filing Facts

CIK

1802768

Ticker

RPRX

Form

4

Source Type

fda

Accession

0001814876-26-000027

Alert Tier

6